DOV KADMON to Biomarkers, Tumor
This is a "connection" page, showing publications DOV KADMON has written about Biomarkers, Tumor.
Connection Strength
0.391
-
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
Score: 0.139
-
The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol. 2005 Jun; 173(6):1923-5.
Score: 0.128
-
CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 2006 Jan; 5(1):78-83.
Score: 0.034
-
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol. 2004 Sep; 172(3):900-4.
Score: 0.030
-
Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
Score: 0.014
-
Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl. 1992; 16H:54-61.
Score: 0.013
-
The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2010 Mar; 13(1):6-11.
Score: 0.011
-
The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18.
Score: 0.008
-
Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003 Apr; 4(3):251-61.
Score: 0.007
-
The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96.
Score: 0.007